Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.

"Conflict-of-interest disclosure: M.S. owns stock in Celaid Therapeutics. T.M. has received grants or contracts from each of Mochida Pharmaceutical, 10.13039/100002491Bristol Myers Squibb, Merck Sharp & Dohme (MSD), AbbVie GK, 10.13039/100008792Novartis Pharma, 10.13039/100008322CSL Behring, 10.13039/501100003769Eisai, 10.13039/501100010486Teijin Pharma, Medical & Biological Laboratorie, KM Biologics, 10.13039/501100007132Otsuka Pharmaceutical, 10.13039/501100004095Kyowa Kirin, 10.13039/501100005612Shionogi, 10.13039/100010795Chugai Pharmaceutical, Takeda Pharmaceutical, and Asahi Kasei Corporation; and has received payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from Pfizer Inc, AbbVie GK, MSD, Meiji Seika Pharma, Janssen Pharma, CSL Behring, Sumitomo Pharma, SymBio Pharmaceuticals, Novartis Pharma, AstraZeneca, Kyowa Kirin Co Ltd, Daiichi Sankyo, Chugai Pharmaceutical, Mochida Pharmaceutical, Asahi Kasei Corporation, Sanofi, Japan Blood Products Organization, Otsuka Pharmaceutical, Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Ono Pharmaceutical, Eisai Pharmaceuticals, and Astellas Pharma. K.U. has received research funding from 10.13039/501100004948Astellas, 10.13039/100006483AbbVie, Bristol Myers Squibb, 10.13039/100005565Janssen, Ono, 10.13039/100019120Otsuka, 10.13039/100010795Chugai, Aperis, 10.13039/501100012030Yakult, MSD, 10.13039/100002429Amgen, Alxion, 10.13039/100017655Incyte, 10.13039/501100003769Eisai, 10.13039/501100004095Kyowa Kirin, Sanfi, SymBio, 10.13039/100006436Celgene, 10.13039/501100022274Daiichi Sankyo, Sumitomo-Dainippon, Nippon Shinyaku, Novartis, Mundi, and 10.13039/100008373Takeda; has served on speaker bureaus for Novartis, AbbVie, Alexion, Incyte, Ono, Kyowa-Kirin, Sanfi, Takeda, Nippon-Shinyaku, Pfizer, and Bristol Myers Squibb; and has served on consulting bureaus for Astellas, Amgen, Alnylam Japan, Alexion, Eisai, Otsuka, Ohara, Kyowa-Kirin, Sanofi, Sando, SymBio, Takeda, Chugai, and Nippon-Shinyaku. The remaining authors declare no competing financial interests."

"Mochida Pharmaceutical; 10.13039/100002491Bristol Myers Squibb; MSD); AbbVie GK; 10.13039/100008792Novartis Pharma; 10.13039/100008322CSL Behring; 10.13039/501100003769Eisai; 10.13039/501100010486Teijin Pharma; Medical & Biological Laboratorie; KM Biologics; 10.13039/501100007132Otsuka Pharmaceutical; 10.13039/501100004095Kyowa Kirin; 10.13039/501100005612Shionogi; 10.13039/100010795Chugai Pharmaceutical; Takeda Pharmaceutical; Asahi Kasei Corporation; 10.13039/501100004948Astellas; 10.13039/100006483AbbVie; Bristol Myers Squibb; 10.13039/100005565Janssen; Ono; 10.13039/100019120Otsuka; 10.13039/100010795Chugai; Aperis; 10.13039/501100012030Yakult; MSD; 10.13039/100002429Amgen; Alxion; 10.13039/100017655Incyte; 10.13039/501100003769Eisai; 10.13039/501100004095Kyowa Kirin; Sanfi; SymBio; 10.13039/100006436Celgene; 10.13039/501100022274Daiichi Sankyo; Sumitomo-Dainippon; Nippon Shinyaku; Novartis; Mundi; 10.13039/100008373Takeda"